• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets

    Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets

  2. UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

    UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

  3. UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

    UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

  4. UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

    UPDATE: Gilead earnings: Lowered expectations could help when company reports first-quarter results

  5. Graft Versus Host Disease (GVHD) Therapeutics Pipeline Report, H1 2017: Review of 61 Companies & Their Drug Profiles - Research and Markets

    Graft Versus Host Disease (GVHD) Therapeutics Pipeline Report, H1 2017: Review of 61 Companies & Their Drug Profiles - Research and Markets

  6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets

    Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets

  7. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  8. Hepatitis C Therapy Approved in China -- WSJ

    Hepatitis C Therapy Approved in China -- WSJ

  9. Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market in Alzheimer's Disease, Asthma, Breast Cancer, Leukemia, Lung Cancer & Lymphoma - Research and Markets

    Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market in Alzheimer's Disease, Asthma, Breast Cancer, Leukemia, Lung Cancer & Lymphoma - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.